Stockreport

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF Itolizumab continues to show clinically meaningful response in highly proteinuric subjectsAt Week 28, 73% of subjects achieved 50% reduction in urine protein creatinine [Read more]